Levofloxacina Hikma

Levofloxacin, the active ingredient in Levofloxacina Hikma, is a fluoroquinolone antibiotic presented as an intravenous formulation for parenteral use. It treats a range of bacterial infections in adult patients.

GNH USA supplies Levofloxacina Hikma as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Levofloxacina Hikma is a fluoroquinolone that targets bacterial DNA replication and is indicated for several serious infections. - Community‑acquired pneumonia: effective against typical and atypical pathogens, improving respiratory outcomes. - Complicated urinary tract infections: eradicates Gram‑negative organisms causing pyelonephritis. - Skin and skin structure infections: treats moderate to severe bacterial cellulitis and wound infections. - Intra‑abdominal infections: covers mixed aerobic and anaerobic bacteria in complicated cases.

Levofloxacina Hikma may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea - Diarrhea - Headache - Dizziness - Rash - Elevated liver enzymes

Serious or Rare Side Effects: - Tendon rupture or tendinitis - QT interval prolongation - Clostridioides difficile‑associated diarrhea - Severe allergic reactions (anaphylaxis) - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Peripheral neuropathy

Before initiating therapy, clinicians should consider several safety measures. - Renal function assessment: adjust dosing in patients with impaired clearance. - Tendon health monitoring: discontinue if tendon pain or swelling occurs. - Cardiac monitoring: avoid in patients with known QT prolongation. - Concurrent corticosteroid use: increase risk of tendon injury. - Hypersensitivity: discontinue at first sign of severe allergic reaction. - Store at below 25°C: keep in original packaging, protect from moisture.

Levofloxacina Hikma can interact with other medicines; some combinations should be avoided while others require close monitoring.

Major Interactions (Avoid): - Tizanidine: may cause profound hypotension. - Antacids containing aluminum or magnesium: reduce levofloxacin absorption. - Warfarin: increased anticoagulant effect, monitor INR. - Cyclosporine: elevated cyclosporine levels, risk of nephrotoxicity. - Other fluoroquinolones: additive toxicity, avoid co‑administration.

Moderate Interactions (Monitor Closely): - Corticosteroids: heightened risk of tendon rupture. - Theophylline: increased plasma concentrations, monitor for toxicity. - NSAIDs: may enhance central nervous system stimulation. - Sulfonylureas: enhanced hypoglycaemic effect, monitor glucose. - Diabetic agents (insulin): possible increased hypoglycaemia.